← Human Trials & Peer-Reviewed Studies
Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males.
Plain-language guide to PMID 8287567 (1993): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 8287567
- Journal
- Clinical endocrinology
- Year
- 1993
- Study type
- Randomized Controlled Trial
- Authors
- Vandeweghe M et al. (3 authors)
- DOI
- 10.1111/j.1365-2265.1993.tb02387.x
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.
Who Took Part
PubMed indexes the participants as adults, men only.
The researchers performed a 6-month randomized, double-blind, placebo-controlled study, followed by 12-24 months of GH treatment in all patients.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the participants nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.
The researchers measured serum IGF-I, serum phosphate, biochemical indices of bone turnover (serum alkaline phosphatase activity, serum osteocalcin, serum carboxyterminal propeptide of type-I procollagen, fasting urinary hydroxyproline/creatinine and calcium/creatinine ratios) and bone mineral content, measured at the forearm and the lumbar spine by single and dual-photon absorptiometry respectively.
What Was Measured
The subject headings attached to it are Bone Density, Bone Remodeling and Growth Hormone.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 1993 (Clinical endocrinology), a journal based in England.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.